When you listen in, you’ll learn about advances like these:

• How Phoenix replaced reactors with particle accelerators, producing neutrons that reduce nuclear materials by a thousand with an inherent “off-switch.”
• How technology Phoenix creates is essential to industrial air and space mechanical production as well as medical diagnosis, specifically radioisotopes in medicine like the molybdenum 99 production.
• Why Shine Medical continues to explore producing isotopes that possess therapeutic attributes for diseases like cancer.
• What other products Phoenix is making such as an electronic machine that should replace Californium 252.

In this podcast, Even Sengbusch, PhD, MBA, and president of Phoenix, discusses the collaboration of Shine Medical and Phoenix. These companies are making headway in neutron production without nuclear reactors and without the accompanying risks and limitations. Dr. Sengbusch describes each company and their respective focus (Greg Piefer, founder and CEO of Shine Medical was unable to join the podcast as planned because of travel issues). Shine Medical grew as an off shoot of Phoenix in 2010 to work on radioisotopes in medicine. Phoenix manufactures neutron generators and Shine uses this isotope technology specifically for medical imaging systems.

Phoenix is collaborating with Shine to manufacture molybdenum 99 production. This isotope has been foundational in medical imaging, but has only two producers across the globe. Phoenix is on its way to becoming a third producer through a completely different non-reactor method that is safer and more efficient. As it decays, molybdenum 99 releases detectable gamma rays, acting as markers for imaging specific organs. The isotope will also adhere to cancer cells, making their detection possible.

For more information, see https://phoenixwi.com/ and https://shinemed.com/.

Podcast: Play in new window | Download | Embed